GlassScriptPhysician profile
Tammy S Pearson
NPI 1447230826
$2,469.38
in general payments reported to CMS, 2019-2025
25 companies · $655 in 2025
The $655 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $436 · 2023: $323 · 2024: $650 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $642.25 | 2021-2025 | Shingrix, Penmenvy, Arexvy |
| Astrazeneca Pharmaceuticals LP | $296.65 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $244.52 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $147.53 | 2021-2025 | |
| Boston Scientific Corporation | $129.87 | 2025 | Watchman Flx |
| Gilead Sciences, INC. | $124.74 | 2024 | Epclusa |
| Kowa Pharmaceuticals America, INC. | $124.74 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.36 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $105.33 | 2024-2025 | Fanapt |
| Abbvie INC. | $102.37 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $77.92 | 2024-2025 | Voquezna |
| Amgen INC. | $51.97 | 2023-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $45.89 | 2023-2025 | Auvelity |
| Electromed, INC. | $43.36 | 2022 | |
| Dexcom, INC. | $30.45 | 2025 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.22 | 2024 | Veozah |
| Lundbeck LLC | $23.72 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $21.95 | 2024 | Xarelto |
| Exact Sciences Corporation | $19.63 | 2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $19.31 | 2025 | Collagenase Santyl |
| Pfizer INC. | $18.13 | 2024 | |
| Alkermes, INC. | $15.83 | 2025 | Lybalvi |
| Abbott Laboratories | $13.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.